United States · FDA National Drug Code directory

Mavyret

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
0074-2625_c1aa97e0-7350-4286-ac17-915bcdf0b08a
Product NDC
0074-2625
Form
TABLET, FILM COATED
Composition / generic term
Glecaprevir and Pibrentasvir
Labeler
AbbVie Inc.
Marketing category
NDA
Marketing start / end (source format)
20170803
Source listing expiry
20271231

Source-listed ingredients

  • PIBRENTASVIR — 40 mg/1
  • GLECAPREVIR — 100 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 4 CARTON in 1 CARTON (0074-2625-04) / 7 BLISTER PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 BLISTER PACK · 0074-2625-04
  • 4 CARTON in 1 CARTON (0074-2625-28) / 7 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PACK · 0074-2625-28
  • 2 CARTON in 1 CARTON (0074-2625-56) / 4 CARTON in 1 CARTON / 7 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PACK · 0074-2625-56
  • 84 TABLET, FILM COATED in 1 BOTTLE (0074-2625-84) · 0074-2625-84

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →